Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
INSULIN HUMAN
Eli Lilly and Company Limited
A10AD01
INSULIN HUMAN
100 IU/ML
Suspension for Injection
Product subject to prescription which may be renewed (B)
Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
Authorised
1996-04-30
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Humulin M3 (Mixture 3) 100 IU/ml Suspension for Injection in cartridge. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains 100 IU human insulin (produced in _E. coli _by recombinant DNA technology). One cartridge contains 3 ml equivalent to 300 IU of biphasic isophane insulin – 30 % soluble insulin / 70 % isophane insulin. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM A suspension for injection in a cartridge. Humulin M3 is a sterile suspension of human insulin in the proportion of 30 % soluble insulin to 70 % isophane insulin. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The dosage should be determined by the physician, according to the requirement of the patient. Humulin M3 should be given by subcutaneous injection but may although not recommended, also be given by intramuscular injection. This formulation should not be administered intravenously. Subcutaneous administration should be in the upper arms, thighs, buttocks or abdomen. Use of injection sites should be rotated so that the same site is not used more than approximately once a month. Care should be taken when injecting any Humulin insulin preparations to ensure that a blood vessel has not been entered. After any insulin injection, the injection site should not be massaged. Patients must be educated to use proper injection techniques. Humulin Mixture formulation is a ready-made defined mixture of soluble and isophane insulin designed to avoid the need for the patient to mix insulin preparations. A patient's treatment regimen should be based on Read the complete document